GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Distribution » Sichuan Goldstone Asia Pharmaceutical Inc (SZSE:300434) » Definitions » Research & Development

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Research & Development : ¥41 Mil (TTM As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sichuan Goldstone Asia Pharmaceutical Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Sichuan Goldstone Asia Pharmaceutical's Research & Development for the three months ended in Mar. 2024 was ¥9 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ¥41 Mil.


Sichuan Goldstone Asia Pharmaceutical Research & Development Historical Data

The historical data trend for Sichuan Goldstone Asia Pharmaceutical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Goldstone Asia Pharmaceutical Research & Development Chart

Sichuan Goldstone Asia Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.54 27.84 37.45 39.19 50.01

Sichuan Goldstone Asia Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.59 10.28 12.16 9.99 8.50

Sichuan Goldstone Asia Pharmaceutical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Goldstone Asia Pharmaceutical  (SZSE:300434) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Sichuan Goldstone Asia Pharmaceutical Research & Development Related Terms

Thank you for viewing the detailed overview of Sichuan Goldstone Asia Pharmaceutical's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Business Description

Traded in Other Exchanges
N/A
Address
8 Jiayuan Road, 8th Floor, District A1, Dadi Xinguanghua Plaza, Chengdu, CHN, 610072
Sichuan Goldstone Asia Pharmaceutical Inc is engaged in development and application of steel-reinforced plastic composite pipe technology, providing customers with steel-reinforced plastic composite pipes from pipe structure, production process to construction technology. The company is also engaged in research and development, production and sales of medicines and health products.

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Headlines

No Headlines